Lymphocele after renal transplant: Prevention and management

Abstract

Lymphocele is a common postoperative complication following renal transplantation, with reported incidence ranging from 0.6% to 38%. Symptomatic lymphoceles, occurring in 5%-10% of recipients, may cause graft dysfunction through ureteric or vascular compression. This minireview provides a comprehensive synthesis of the epidemiology, pathophysiology, risk factors, prevention, diagnosis, and management of post-transplant lymphoceles. Prevention strategies include meticulous surgical ligation of lymphatics, prophylactic peritoneal fenestration, and delaying the use of mammalian target of rapamycin inhibitors in the early post-transplant period. Diagnosis is best achieved using ultrasound, with computed tomography or magnetic resonance imaging reserved for complex cases. Management follows a stepwise approach: Conservative observation for small asymptomatic collections, percutaneous drainage with or without sclerotherapy for symptomatic cases, and laparoscopic marsupialization for refractory or complicated lymphoceles. Novel techniques, including intraoperative lymphangiography and bioengineered sealants, represent promising future strategies for addressing these challenges. This minireview highlights the importance of integrating surgical refinement, tailored immunosuppression, and emerging technologies to optimize outcomes in renal transplant recipients.

Key Words: Lymphocele; Renal transplantation; Complications; Immunosuppression; Prevention; Management; Marsupialization

Core Tip: Lymphocele, a frequent complication after renal transplantation, results from lymphatic leakage, causing pelvic fluid accumulation. Incidence varies (0.6%-38%), with symptomatic cases (5%-10%) being at risk of graft dysfunction. Prevention emphasizes meticulous surgical ligation, peritoneal fenestration, and avoiding mammalian target of rapamycin inhibitors early post-transplant. Ultrasound aids diagnosis, while management ranges from conservative monitoring for small lymphoceles to sclerotherapy or laparoscopic marsupialization for persistent cases. Emerging techniques, like intraoperative lymphangiography, show promise. Tailored immunosuppression and refined surgical approaches are critical for reducing lymphocele morbidity.

INTRODUCTION

Lymphocele is a common postoperative complication following renal transplantation, characterized by the accumulation of lymphatic fluid in the retroperitoneal space, typically near the transplanted kidney or pelvic region. This condition arises from the disruption of lymphatic channels during surgical dissection, resulting in fluid leakage and the formation of a lymphocele, a pseudocyst lacking an epithelial lining[1]. Lymphoceles can cause significant morbidity, including pelvic pain, lower extremity swelling, infection, and graft dysfunction due to compression of the ureter or vascular structures[2].

Reported incidence rates vary widely, from 0.6% to 38%, with symptomatic lymphoceles requiring intervention occurring in approximately 5%-10% of cases[3-5]. The variability in incidence reflects differences in surgical techniques, diagnostic criteria, and follow-up protocols.

Given its potential to impact transplant outcomes, effective prevention and management strategies are critical. This mini-review synthesizes evidence to guide prevention and management, emphasizing tailored strategies to mitigate morbidity.

EPIDEMIOLOGY

The incidence of lymphocele after renal transplantation varies widely, influenced by diagnostic methods, imaging frequency, and study design. A 2024 meta-analysis reported a pooled incidence of 7.5% overall (5.5% with electrocauterization vs 9.3% with ligation), with symptomatic lymphoceles (requiring intervention) occurring in 5%-10% of renal transplant recipients[3]. A 2021 retrospective study of 452 recipients found a lower overall incidence of 6.4%, with 24.1% of these cases being asymptomatic[4]. Another recent review estimated an overall incidence of up to 20%, highlighting the role of routine imaging in detecting asymptomatic cases[5]. The wide range (0.6%-38%) is attributed to differences in surgical expertise, immunosuppressive regimens, and the sensitivity of diagnostic tools, such as ultrasound[1,2]. Symptomatic lymphoceles, though less common, pose significant clinical challenges due to their potential to cause graft dysfunction or infection.

PATHOPHYSIOLOGY

Lymphocele formation results from the disruption of lymphatic vessels during renal transplant surgery, particularly during dissection of the iliac vessels or mobilization of the donor kidney[1]. Lymphatic fluid, rich in lymphocytes and proteins, leaks into the retroperitoneal space, forming a lymphocele. Two primary sources contribute to this leakage: The recipient’s pelvic lymphatics and the donor kidney’s hilar lymphatics[2]. Figure 1 illustrates the overall pathophysiology of lymphocele formation following renal transplantation.

Figure 1 Flowchart illustrating the pathophysiology of lymphocele formation following renal transplantation. mTOR: Mammalian target of rapamycin.

Factors exacerbating lymphatic leakage include extensive perivascular dissection, inadequate ligation of lymphatics, and the use of immunosuppressive agents such as mammalian target of rapamycin (mTOR) inhibitors (e.g., sirolimus), which impair lymphatic vessel regeneration[6,7]. Inflammation or acute rejection episodes can also lead to increased capillary permeability and interstitial fluid accumulation, which in turn elevates the lymphatic load and exacerbates leakage from disrupted channels[2]. Recipient factors, such as obesity or diabetes, can alter tissue healing and lymphatic pressure, increasing the likelihood of fluid accumulation[5].

Table 1 highlights the key risk factors for lymphocele formation. Patient-related factors, such as male sex, obesity, diabetes, and a history of peritoneal dialysis, are associated with higher lymphocele rates, likely due to altered tissue healing or increased lymphatic pressure[4,5,8]. A 2021 study also identified age (50-65 years) and polycystic kidney disease as significant risk factors[4].

Table 1 Risk factors for lymphocele formation.

Risk factor category	Specific factors
Patient-related	Male sex, obesity, diabetes, peritoneal dialysis, age 50-65 years, polycystic kidney disease
Surgery-related	Deceased donor, prolonged cold ischemia time, extensive retroperitoneal dissection
Immunosuppression-related	High-dose corticosteroids, mTOR inhibitors

mTOR: Mammalian target of rapamycin.

Surgery-related factors include kidneys from deceased donors, prolonged cold ischemia time, and extensive retroperitoneal dissection[4,8]. Conversely, minimally invasive techniques, such as laparoscopic donor nephrectomy, have been shown to reduce incidence by minimizing tissue trauma[9].

Immunosuppression-related factors, particularly high-dose corticosteroids and mTOR inhibitors, are strongly linked to lymphocele formation[6,7]. A 2011 cohort study reported a higher incidence in patients on sirolimus-based regimens, attributed to the anti-angiogenic and lymphangiogenic effects of sirolimus[6]. Despite these risks, mTOR inhibitors, such as sirolimus, remain integral to select regimens due to their anti-proliferative effects in reducing malignancy risk post-transplant and as calcineurin inhibitor-sparing agents to mitigate nephrotoxicity (e.g., in patients with a history of skin cancer or chronic allograft nephropathy)[7].

PREVENTION STRATEGIES

Preventing lymphocele formation is a cornerstone of optimizing renal transplant outcomes. Figure 2 outlines a multiphase flowchart algorithm for the prevention of lymphocele formation following renal transplantation.

Figure 2 Multiphase flowchart algorithm for the prevention of lymphocele formation following renal transplantation. OR: Odds ratio.

Meticulous surgical technique

Careful ligation or clipping of lymphatic vessels during iliac vessel preparation is critical. A 2024 systematic review and meta-analysis recommended using non-absorbable sutures or titanium clips to seal lymphatics effectively[3]. Minimizing retroperitoneal dissection and preserving lymphatic channels around the donor kidney further reduces the risk of leakage[1]. The use of minimally invasive techniques, such as laparoscopic donor nephrectomy, has been associated with lower rates of lymphoceles[9].

Fibrin sealants

Application of fibrin glue or sealants to the surgical bed has shown promise in reducing lymphatic leakage. A 2016 randomized controlled trial reported a significant reduction in postoperative fluid collections, including lymphoceles, with the use of fibrin sealant, although cost-effectiveness remains a concern[10].

Prophylactic peritoneal fenestration

A 2017 systematic review of three trials involving 437 transplantations found that peritoneal fenestration significantly reduced clinically symptomatic lymphoceles [unadjusted odds ratio (OR) = 0.23, 95% confidence interval (CI): 0.09-0.64] and overall postoperative fluid collections (unadjusted OR = 0.49, 95%CI: 0.28-0.88) without increasing other surgical complications[2,11]. However, methodological limitations, such as variable endpoint definitions and selection bias, highlight the need for further research.

Immunosuppression optimization

Avoiding or delaying mTOR inhibitors in the early post-transplant period may reduce the risk of lymphocele. A 2011 cohort study found sirolimus use was independently associated with a higher incidence of lymphocele (adjusted hazard ratio = 2.8, 95%CI: 1.4-5.6) due to impaired lymphatic regeneration[6,7]. The Kidney Disease: Improving Global Outcomes guidelines recommend calcineurin inhibitors (e.g., tacrolimus) as the primary immunosuppressive agent for the first 3 months to 6 months post-transplant[12].

Surgical drains

The use of pelvic drains intraoperatively is controversial. A 2021 systematic review and meta-analysis of 18 studies (n = 3456) found no significant reduction in lymphocele incidence with routine drain use (OR = 0.85, 95%CI: 0.62-1.17; P = 0.32) but highlighted an increased risk of surgical site infections (OR = 1.62, 95%CI: 1.21-2.17; P = 0.001)[13]. Current Kidney Disease: Improving Global Outcomes and environmental risk assessment guidelines do not recommend routine prophylactic drains due to the infection risk outweighing any potential benefits, favouring selective use in high-risk cases (e.g., obesity with body mass index > 30 kg/m²)[14].

DIAGNOSIS

Lymphoceles are typically diagnosed using imaging, with ultrasound being the first-line modality due to its accessibility, cost-effectiveness, and lack of radiation exposure[1,15]. It allows real-time assessment of size, location, and septations. Computed tomography or magnetic resonance imaging may be employed for complex cases or to differentiate lymphoceles from other fluid collections, such as hematomas, urinomas, or abscesses[2]. Figure 3 depicts a stepwise flowchart algorithm for the diagnosis and management of suspected lymphocele following renal transplantation.

Figure 3 Stepwise flowchart algorithm for the diagnosis and management of suspected lymphocele following renal transplantation. CT: Computed tomography; MRI: Magnetic resonance imaging.

Symptomatic lymphoceles may present with: (1) Pelvic pain; (2) Lower extremity swelling; (3) Hydronephrosis (34.4% of cases in one study)[4]; and (4) Graft dysfunction due to compression of the ureter or vascular structures[2,4].

Asymptomatic lymphoceles, which constitute a significant proportion (24.1% in one study), are often detected incidentally during routine post-transplant imaging, typically within 1-3 months post-surgery[4]. Peak incidence of symptomatic lymphocele occurs at 4-8 weeks post-transplant[5]. Urinary tract infections, a common comorbidity, can complicate diagnosis and management, occurring in up to 50% of recipients within the first year[16].

MANAGEMENT

The management of lymphoceles depends on their size, symptoms, and associated complications. A stepwise approach is commonly employed: (1) Conservative management: Small, asymptomatic lymphoceles (< 5 cm) are often managed with serial ultrasound monitoring. Most resolve spontaneously within a few months[2]. No intervention is required unless growth or symptoms develop; (2) Percutaneous interventions: For symptomatic or significant lymphoceles, ultrasound-guided aspiration is a minimally invasive first step. However, recurrence rates are high (up to 59%) due to persistent lymphatic leakage[2]. Sclerotherapy, involving the injection of sclerosing agents such as povidone-iodine, ethanol, or doxycycline after aspiration, demonstrates superior efficacy. A 2021 systematic review demonstrated more favourable success rates for sclerotherapy compared to simple drainage alone[17]. One early study reported 89% resolution rate using povidone-iodine[18]. Combined aspiration and sclerotherapy is therefore preferred for most symptomatic cases; (3) Surgical interventions: For refractory, recurrent, or complicated lymphoceles, surgical management is indicated. Laparoscopic marsupialization, which creates a window between the lymphocele and the peritoneal cavity to allow fluid reabsorption, is the standard approach due to its high success rate (94%) and minimal recurrence (< 6%) in analogous cases[19]; transplant-specific rates are approximately 90%-95%[2]. Open surgical fenestration is an alternative, but it is less commonly used due to its invasiveness. In rare cases, lymphangiography with lymphatic embolization is used for persistent leaks; however, this technique is technically challenging and not widely available[20]; and (4) Management of complications: Infected lymphoceles require prompt antibiotic therapy and drainage to prevent graft loss, with percutaneous approaches preferred initially[19]. Lymphoceles causing graft dysfunction due to compression necessitate urgent decompression via aspiration or surgery[20]. Urinary tract infections in this context warrant targeted antimicrobials, as they are common in renal transplant patients and can increase the risk of infection[21].

EMERGING TRENDS

Recent advancements in lymphocele prevention and management include the use of intraoperative lymphangiography with indocyanine green fluorescence to guide precise ligation of lymphatic vessels. A 2016 study demonstrated the feasibility and safety of this technique in reducing postoperative lymphatic complications during renal transplantation; however, though larger randomized trials are needed to confirm its long-term efficacy[22]. Research into bioengineered sealants with enhanced biocompatibility is ongoing, primarily in preclinical stages, with potential to reduce lymphatic leakage more effectively than current fibrin-based sealants[23]. Additionally, personalized immunosuppression - guided by clinical factors such as rejection history, infection risk, and biomarker levels (e.g., donor-specific antibodies) - can help minimize lymphocele risk while optimizing graft function and reducing over-immunosuppression[24]. These innovations highlight the evolving landscape of transplant care and the need for further research to validate their clinical effectiveness.

CONCLUSION

Lymphocele remains a notable challenge in renal transplantation, particularly for symptomatic cases requiring intervention, with a complex interplay of surgical, pharmacological, and patient-related factors contributing to its occurrence. Prevention through meticulous surgical techniques, prophylactic measures like peritoneal fenestration, and optimized immunosuppression can significantly reduce incidence. Management strategies, ranging from conservative monitoring to surgical intervention, must be tailored to the clinical presentation, with laparoscopic marsupialization offering high efficacy for refractory cases. While recent studies have advanced our understanding, methodological limitations and variability in current evidence underscore the need for high-quality randomized controlled trials to standardize prevention and treatment protocols. Ongoing research into novel techniques, such as intraoperative lymphangiography and bioengineered sealants, holds promise for further improving outcomes in renal transplant recipients.